Call for proposals
Innovative Medicines Initiative (IMI): “Exploitation of IMI project results”
- IMI2-2017-11-01
Objective and description
A
new call for proposals has been published under the Innovative
Medicines Initiative (IMI): “Exploitation of IMI project results” -
IMI2-2017-11-01
The Innovative Medicines Initiative (IMI) is
a jointly funded partnership between the European Union, represented by
the European Commission, and the European Federation of Pharmaceutical
Industries and Associations (EFPIA).
The IMI 2 Joint Undertaking (IMI2 JU) aims to
support research related to the future of medicine should in areas
where societal, public health and biomedical industry competitiveness
goals are aligned and require the pooling of resources and greater
collaboration between the public and private sectors, with the
involvement of small and mediumsized enterprises (SMEs). The areas
should be of public health interest, as identified by the World Health
Organisation (WHO) report on priority medicines for Europe and the
World.
This call for proposals aims at providing
a starting/short term support to develop enabling solutions to ensure
that significant results from IMI projects become fully exploitable,
available to all relevant end users, and/or fully sustainable in the
long term and in their own right. This will ensure that the significant
outputs, important samples and/or data that have been generated by the
large public-private investments are maintained and made available for
future research by the whole scientific community and that important
findings are integrated in general research and medical practice in
support of the objectives of IMI2.
Applicants should be aware that only the project results identified in the list of results available on the IMI2 JU website http://www.imi.europa.eu/content/imi-2-call-11
are within the scope of this Call. As such, applicants must clearly
indicate through their proposals which results they are utilising.
Eligible applicants
Only the following participants shall be eligible for funding from the Innovative Medicines Initiative 2 Joint Undertaking:
1. legal entities established in a Member State or an associated country, or created under Union law and which fall within one of the following categories:
· micro,
small and medium-sized enterprises and other companies with an annual
turnover of EUR 500 million or less, the latter not being affiliated
entities of companies with an annual turnover of more than 500 million;
the definition of ‘affiliated entities’ within the meaning of Article
2(1)(2) of Regulation (EU) No 1290/2013 shall apply mutatis mutandis;
· secondary and higher education establishments;
· non-profit
organisations, including those carrying out research or technological
development as one of their main objectives or those that are patient
organisations.
2. the Joint Research Centre
3. international European interest organisations
Part
C of the General Annexes to the Horizon 2020 – Work Programme 2016 –
2017 apply mutatis mutandis for the actions covered by this Call for
proposals. Since the aforementioned calls refer to Research and Innovation actions eligible are consortia of at least three legal entities.
Each of the three must be established in a different EU Member State or
Horizon 2020 associated country. All three legal entities must be
independent of each other.
Budget
The total financial contribution from the IMI2 JU is a maximum of EUR 5 000 000.
The funding rate from IMI2 JU is 100% of the eligible costs.
Proposals
should include an appropriate duration for the action in relation to
the activities and action work plan but should be no longer than 24 months.
Deadline for proposals’ submission
The deadline of this call is 24 October 2017, 17:00 (Brussels local time).
Applicants must submit their proposal electronically, following the link on the submission service.
Further information
Please find attached the call documents.
More information: http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/topics/imi2-2017-11-01.html
Kind regards,
Flora Stavropoulou
Intern
European Office of Cyprus
Rue du Luxembourg 3, 2nd floor
B-1000, Brussels
Tel/Fax: +32 (0) 2 280 22 85
E-mail: eoc.brussels2@ucy.ac.cy
PLEASE NOTE THAT THE GREEK TRANSLATION IS PROVIDED AT REQUEST OF ANY INTERESTED MEMBER (based on the decision of 22.12.2016 of the EOC Administrative Council).
